Vidarbha News

Acute Myeloid Leukemia Market is expected to grow at a CAGR OF 22% During the Study Period [2018-2030], States DelveInsight

 Breaking News
  • No posts were found

Acute Myeloid Leukemia Market is expected to grow at a CAGR OF 22% During the Study Period [2018-2030], States DelveInsight

August 11
22:09 2021
Acute Myeloid Leukemia Market is expected to grow at a CAGR OF 22% During the Study Period [2018-2030], States DelveInsight
Acute Myeloid Leukemia Market

Acute myeloid leukemia (AML), also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. AML can involve tissues outside the bone marrow and blood, including lymph nodes, the brain, skin, and other parts of the body.

DelveInsight has added a new research study on Acute Myeloid Leukemia Market Report with detailed information on the overview, market insights, drugs industry, treatment, growth, size, share, trends, during the forecast period of 2017 to 2030


Some key facts of Acute Myeloid Leukemia Market Report:

  • The Acute Myeloid Leukemia Market will increase because of an upsurge in research and development, enriched understanding of the disease, increased AML incidence, and imminent launches of the drugs. However, the AML market growth might be hindered due to the high cost of therapy, toxic therapies, limitations in designing clinical trials, and low survival rates. 
  • The AML treatment landscape has remained virtually unchanged for almost five decades. There have been recent approvals in frontline patient’s intensive chemotherapy eligible patients such as VYXEOS (Jazz Pharmaceuticals), RYDAPT (Novartis), MYLOTARG (Pfizer), and ONUREG (BMS), and in ineligible patients Daurismo (Pfizer), TIBSOVO (Agios Pharma), and VENCLEXTA (Abbvie). Approvals relapsed/refractory and salvage settings include IDHIFA (BMS), XOSPATA (Astellas Pharma), and the recent approval of VANFLYTA (Daiichi Sankyo).
  • Despite the new therapies, there are several limitations associated with the current milieu of drugs. The high relapse rate in the high-risk population remains a significant concern. The overall survival in the elderly population remains relatively low.
  • Various new therapies are in development with a focus on mentioned limitations of the currently approved drugs. Some of the most prominent ones include ASTX 727 (Astex Pharmaceutical), CPI-613 (Rafael Pharmaceuticals), CX-01 (Chimerix), APL-106 (GlycoMimetics Incorporated), Quizartinib (Daiichi Sankyo), MLN-4924 (Millennium Pharmaceuticals), Iomab-B (Actinium Pharmaceuticals), SLS-001 (Sellas Life Sciences),  ARO-002 (Arog Pharmaceuticals), MGD-006 (MacroGenics),  FT-2102 (Forma Therapeutics), DF9-10917 (Delta-Fly Pharma) and SNDX-5613 (Syndax Pharmaceuticals).


Request Sample Report @


Acute Myeloid Leukemia Market Report Highlights

  • In the coming years, the Acute Myeloid Leukemia Market is set to change due to the rising awareness of the disease, and the Favorable Environment for New Anti-infective Modalities; which would expand the market’s size to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Acute Myeloid Leukemia (AML) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Acute Myeloid Leukemia (AML). The launch of emerging therapies will significantly impact the Acute Myeloid Leukemia (AML) market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.


List of Key Players involved in the Acute myeloid leukemia Market report

  • Pfizer
  • Bristol Myers Squibb
  • Agios Pharmaceuticals
  • Abbvie
  • Jazz Pharmaceuticals
  • Astellas Pharma
  • Pfizer
  • Novartis Oncology
  • Daiichi Sankyo.
  • Bristol Myers Squibb
  • AstraZeneca/Astex Pharmaceuticals, Inc.
  • Chimerix
  • Takeda
  • Rafael Pharmaceuticals Inc.
  • Delta-Fly Pharma
  • GlycoMimetics Incorporated
  • BerGenBio ASA
  • MacroGenics
  • Syndax Pharmaceuticals
  • Arog Pharmaceuticals
  • Forma Therapeutics
  • Sellas Life Sciences Group
  • Actinium Pharmaceuticals
  • Clear Creek Bio Inc.
  • CellCentric Ltd.
  • Biosight Ltd.
  • Astex Pharmaceuticals, Inc.
  • Curis, Inc.
  • NexImmune Inc.
  • Immunomedics, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Incyte Corporation
  • Aprea Therapeutics
  • Immunicum/DCPrime BV
  • GT Biopharma, Inc.
  • Hanmi Pharmaceutical Company Limited
  • Cardiff Oncology
  • Bio-Path Holdings
  • Actinium Pharmaceuticals
  • Aptevo Therapeutics
  • Synimmune GmbH
  • GEMoaB Monoclonals
  • ImmunoGen, Inc.
  • AGC Biologics S.p.A.
  • Precigen, Inc.
  • Novartis Pharmaceuticals
  • Xencor, Inc./Novartis
  • Celgene/Bristol Myers Squibb
  • And many others


Request Sample Report @


Acute Myeloid Leukemia Therapies are:

·         ASTX 727

·         CPI-613

·         CX-01

·         APL-106

·         Quizartinib

·         MLN-4924

·         Iomab-B

·         SLS-001

·         ARO-002

·         MGD-006

·         FT-2102

·         DF9-10917

·         SNDX-5613

·         And Many More


Request Sample Report @


Table of Content

  1. Key Insights
  2. Report Introduction
  3. Acute Myeloid Leukemia (AML) Market Overview at a Glance
  4. Executive Summary of Acute Myeloid Leukemia (AML)
  5. Disease Background and Overview
  6. Epidemiology and Patient Population
  7. Organizations contributing towards Acute Myeloid Leukemia (AML)
  8. Case Reports
  9. Patient Journey
  10. Marketed Therapies
  11. Emerging Therapies
  12. Other Promising Therapies
  13. Acute Myeloid Leukemia (AML): Seven Major Market Analysis
  14. Market Drivers
  15. Market Barriers
  16. SWOT Analysis
  17. Unmet Needs
  18. Market Access
  19. KOL Views
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States